Dr. Peter Nigrovic is Chief, Division of Immunology, Boston Children’s Hospital and Prince Turki bin Abdul Aziz al Saud Professor of Pediatrics and Medicine at Harvard Medical School, where he is a pediatric and adult rheumatologist at Boston Children’s Hospital and at the Brigham and Women’s Hospital. His laboratory studies basic mechanisms of inflammation, with a focus on autoimmune arthritis in children and adults. The lab has contributed to the understanding of how mast cells trigger joint inflammation; defined new mechanisms regulating neutrophil migration and monocyte development; and identified a direct role for megakaryocytes in systemic immunity and inflammation, including a new form of cell-in-cell interaction termed emperipolesis. Studies in IgG Fc glycans established estrogen as the first in vivo modulator of IgG glycosylation, defining a novel connection between sex and immunity. His group developed SNP-seq to identify causative non-coding variants from genome wide association study data, helping to bridge the gap between GWAS and mechanism in polygenic diseases including rheumatoid arthrutis, juvenile idiopathic arthritis (JIA), and lupus. Clinically, his principal interest is JIA. He has contributed to the understanding of biological subcategories within this disease family, and his studies of its most explosive form, systemic JIA, helped to shift the paradigm of treatment toward a biologics-first approach. In 2005, he founded the Brigham’s Center for Adults with Pediatric Rheumatic Illness (CAPRI) to provide for the transition and long-term care of patients with arthritis and other rheumatic diseases of childhood. He is past chair of translational research for the pediatric rheumatology research collaborative Childhood Arthritis and Rheumatology Research Alliance (CARRA), designed and co-founded the US/Canadian pediatric rheumatology mentoring group AMIGO, leads the NIH-funded Joint Biology Consortium arthritis research infrastructure, and is deputy editor of the journal Arthritis & Rheumatology.